Efficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic review
Leber A, Ramachandra R, Ceban F, Kwan A, Rhee T, Wu J, Cao B, Jawad M, Teopiz K, Ho R, Le G, Ramachandra D, McIntyre R. Efficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic review. Expert Opinion On Pharmacotherapy 2024, 25: 467-476. PMID: 38515004, DOI: 10.1080/14656566.2024.2334424.Peer-Reviewed Original ResearchPositive and Negative Syndrome ScalePANSS total score changeTotal score changeBaseline to week 5Randomized controlled trialsNegative Syndrome ScaleSchizophrenia spectrum disordersPlacebo groupScore changesSyndrome ScaleTreatment of adultsSpectrum disorderSchizophreniaXanomelineWeek 5Dry mouthClinical Trials RegistryTreatment avenuesPlaceboSide effectsPreclinical trialsTrials RegistryControlled trialsPRISMA guidelinesSystematic review